<DOC>
	<DOC>NCT00203164</DOC>
	<brief_summary>This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Patients must have completed the Week 26 visit of TVP 1012/133 (Visit 06) in accordance with the protocol. Women must be postmenopausal, surgically sterile, or using adequate birth control methods. Women of childbearing potential must have a negative pregnancy test at Baseline/Month 0. Patients must be willing and able to give informed consent. Serious or severe, test drugrelated (probable or definite) adverse reaction in study TVP 1012/133. Premature discontinuation from study TVP 1012/133 for any reason. A clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation. Such conditions may include cardiovascular, pulmonary, hepatic, renal, or metabolic diseases; or malignancies, as determined by medical history, physical exam, skin evaluation, laboratory tests, chest xray, or electrocardiogram (ECG).</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>